Preventing neuropathy and improving anti-cancer chemotherapy with a carbazole-based compound

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a persistent adverse effect of cancer treatment, lacking preventative measures.
• Existing treatments often involve dose reduction, compromising therapeutic efficacy.
• Novel therapeutic strategies are needed to mitigate CIPN without affecting anti-cancer activity.

Purpose of the Study:

• To introduce Carba1, a novel bi-functional carbazole compound designed to prevent CIPN.
• To elucidate the dual mechanisms of action of Carba1 in mitigating neurotoxicity.
• To evaluate the efficacy and safety of Carba1 in preclinical models.

Main Methods:

• Carba1's interaction with tubulin and activation of NAMPT were investigated.
• In vitro neuroprotection assays were performed using paclitaxel, cisplatin, and bortezomib.
• In vivo efficacy was assessed in a rat model of paclitaxel-induced neuropathy.
• Tumor growth and therapeutic efficacy of paclitaxel were evaluated in the presence of Carba1.

Main Results:

• Carba1 demonstrated neuroprotective effects against paclitaxel, cisplatin, and bortezomib-induced neurotoxicity in vitro.
• Carba1 significantly reduced paclitaxel-induced neuropathy in vivo without compromising its anti-cancer efficacy.
• Carba1 activates NAMPT, enhancing neuronal and Schwann cell resilience via metabolic rewiring.
• Carba1 derivatives showed potential for dual synergistic/neuroprotective or exclusive neuroprotective activities.

Conclusions:

• Carba1 is a promising therapeutic candidate for preventing CIPN.
• The dual mechanism of Carba1 offers a novel approach to managing chemotherapy side effects.
• Successful clinical translation of Carba1 could significantly improve cancer patient outcomes and quality of life.